BLU-222 for Solid Cancers
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you must stop all current medications, but you cannot take any prohibited medications or herbal remedies that cannot be stopped at least 2 weeks before starting the study drug.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop your current medications, but it mentions that you cannot take certain prohibited medications or herbal remedies within 2 weeks before starting the study drug.
What data supports the idea that BLU-222 for Solid Cancers is an effective drug?
The available research does not provide any specific data on the effectiveness of BLU-222 for Solid Cancers. Instead, it focuses on other treatments for metastatic breast cancer, such as combinations of docetaxel, bevacizumab, and other drugs. Without direct data on BLU-222, we cannot compare its effectiveness to these other treatments.12345
What safety data is available for BLU-222 in solid cancers?
The provided research does not contain any safety data for BLU-222 or its variants. The studies focus on other treatments such as eribulin, paclitaxel, carboplatin, trastuzumab, pertuzumab, and cisplatin, primarily in breast cancer patients. No information on BLU-222 is available in these abstracts.678910
Is the drug BLU-222 a promising treatment for solid cancers?
What is the purpose of this trial?
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-222, a selective inhibitor of CDK2.
Eligibility Criteria
This trial is for adults with certain advanced solid tumors, including breast cancer, ovarian cancer, endometrial cancer, and stomach cancer that have worsened despite standard treatments. Participants must not be in a health crisis due to their tumor or have serious heart issues or uncontrolled infections. Women of childbearing potential and men must agree to use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BLU-222 as a single agent or in combination with other drugs during dose escalation and expansion phases
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- BLU-222
Find a Clinic Near You
Who Is Running the Clinical Trial?
Blueprint Medicines Corporation
Lead Sponsor